Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma.

Created on 12 Oct 2026

Authors

Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus G Berdeja, Alexander M Lesokhin, Jessica J Liegel, Adriana Rossi, Alex Lieberman-Cribbin, Saad Z Usmani, Binod Dhakal, Samir Parekh, Hui Li, Feng Wang, Rocio Montes de Oca, Vicki Plaks, Huabin Sun, Arnob Banerjee, Jordan M Schecter, Nikoletta Lendvai, Deepu Madduri, Tamar Lengil, Jieqing Zhu, Mythili Koneru, Muhammad Akram, Nitin Patel, Octavio Costa Filho, Andrzej J Jakubowiak, Peter M Voorhees

Published in

Future oncology (London, England). Pages 1-12. Oct 12, 2026. Epub Oct 12, 2026.

PMID:
42860893
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement